2nd Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$330,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 800/S.806, a bill to remove the prompt pay discount between the manufacturer and the distributor from the providers Medicare Part B drug reimbursement. H.R. 1416, Cancer Patient Protection Act of 2013.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —
MATT BROW —
KEAGAN R LENIHAN —
GEOFF WERTH —

Contacted: Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 800 (113th), S. 806 (113th), H.R. 1416 (113th)

Taxation/Internal Revenue Code TAX

Implementation of the new medical device tax. Proposals to repeal LIFO.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: SENATE; Food & Drug Administration (FDA); Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES

Health Issues HCR

Incentives for health information technology, Affordable Care Act implementation, and other healthcare policy issues. Proposed regulation of medical software. Food and Drug Administration Safety and Innovacation Act.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —
MATT BROW —
KEAGAN R LENIHAN —
GEOFF WERTH —

Contacted: HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); Food & Drug Administration (FDA); SENATE

Veterans VET

Existing Department of Veterans' Affairs Pharmaceutical Prime Vendor contract.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: Natl Economic Council (NEC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Pharmacy issues, prescription drug supply chain issues, including security of the supply chain, drug shortages, prescription drug abuse and diversion.

LobbyistCovered position, as disclosed
ANN RICHARDSON BERKEY —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.